Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

27 juin 2018 08h30 HE | Source: Hemispherx Biopharma, Inc.

Hemispherx Opens FDA-Approved Reimbursement Based Expanded Access Treatment Program for ME/CFS to New Enrollees at Approved Clinical Sites in Nevada and North Carolina

ORLANDO, Fla., June 27, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) has announced the immediate expansion of its Treatment Protocol/Expanded Access Programs for ME/CFS in...
15 juin 2018 10h19 HE | Source: Hemispherx Biopharma, Inc.

Hemispherx Releases First 8,500 Vial Lot of Ampligen to Supply Expanded Access Programs in the United States, Europe and Canada for ME/CFS and Pancreatic Cancer and Announces Successful Finish of Second Commercial Size Lot

ORLANDO, Fla., June 15, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) has announced the successful completion of the first phase of its Ampligen production plan. The first...
05 juin 2018 11h21 HE | Source: Hemispherx Biopharma, Inc.

Hemispherx Announces New Data Showing Ampligen’s Positive Role in Reprograming Tumor Microenvironment

ORLANDO, Fla., June 05, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) announced today that its TLR3 agonist Ampligen outperformed two other TLR3 agonists, poly IC and...
31 mai 2018 08h30 HE | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma and Roswell Park Plan Phase I/II Study of Ampligen Plus Checkpoint Inhibitors

ORLANDO, Fla., May 31, 2018 (GLOBE NEWSWIRE) -- Roswell Park Comprehensive Cancer Center (Roswell Park) and Hemispherx Biopharma, Inc. (NYSE American:HEB) plan to expand their existing scientific...
16 mai 2018 14h19 HE | Source: Hemispherx Biopharma, Inc.

CORRECTING AND REPLACING: Hemispherx Biopharma Reports First Quarter 2018 Financial Results and Provides Business Update

ORLANDO, Fla., May 16, 2018 (GLOBE NEWSWIRE) -- In a release issued earlier today by Hemispherx Biopharma, Inc. (NYSE American:HEB) with the same headline, the net loss from operations was incorrect...
16 mai 2018 08h30 HE | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Reports First Quarter 2018 Financial Results and Provides Business Update

ORLANDO, Fla., May 16, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), an advanced specialty pharmaceutical company engaged in the treatment of serious and debilitating...
14 mai 2018 08h30 HE | Source: Hemispherx Biopharma, Inc.

Hemispherx to Present at the 4th Annual Immuno-Oncology: BD&L and Investment Forum

ORLANDO, Fla., May 14, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) announced today that it will be presenting at the 4th Annual Immuno-Oncology: BD&L and Investment...
10 mai 2018 08h30 HE | Source: Hemispherx Biopharma, Inc.

Hemispherx to Present at the 8th Annual LD Micro Invitational

ORLANDO, Fla., May 10, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) announced today that it will be presenting at the 8th Annual LD Micro Invitational on Monday, June 4 at...
02 mai 2018 08h30 HE | Source: Hemispherx Biopharma, Inc.

Hemispherx Provides an Update to Stockholders Highlighting Cancer Focus and $10 Million Booked Since Start of Year Will Support Increased Production of Ampligen for Immuno-Oncology Clinical Trials

ORLANDO, Fla., May 02, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) would like to share a letter with its stockholders today, highlighting 2017 results, recent...
20 avr. 2018 09h28 HE | Source: Hemispherx Biopharma, Inc.

Hemispherx Announces Pricing of $2.57 Million Registered Direct Offering at a Premium to Market

ORLANDO, Fla., April 20, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) (“Hemispherx” or the “Company”), a research and development and emerging commercial growth company...

Page précédente